Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Eicosapentaenoic Acid

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: Eicosapentaenoic Acid. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-005634-12 Sponsor Protocol Number: EPA/POL/02 Start Date*: 2006-06-12
    Sponsor Name:S.L.A. Pharma (UK) Ltd
    Full Title: The effect of two dose levels of eicosapentaenoic acid (EPA) on apoptosis and cell proliferation in the colonic mucosa of patients with a history of colonic polyps.
    Medical condition: Sporadic colonic adenomata
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003029-11 Sponsor Protocol Number: 2012-489 Start Date*: 2012-09-10
    Sponsor Name:Steen Stender
    Full Title: Ethyl ester Versus Triglyceride formulations of long chained omega-3 fatty acids in moderate hypertriglyceridemia - a randomized placebo-controlled clinical trial (EVT)
    Medical condition: Hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    15.0 10027433 - Metabolism and nutrition disorders 10071235 Combined hyperlipidemia LLT
    15.0 10010331 - Congenital, familial and genetic disorders 10060754 Type IV hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003048-37 Sponsor Protocol Number: HSJC-CAR-01-2015 Start Date*: 2015-11-13
    Sponsor Name:Juan Luis Bonilla Palomas
    Full Title: Effect of ?-3 polyunsaturated fatty acids on serum albumin concentration in patients with acute heart failure, hypoalbuminemia, and high inflammatory activity
    Medical condition: Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002836-18 Sponsor Protocol Number: EPA/POL/03 Start Date*: 2006-10-09
    Sponsor Name:S.L.A. Pharma (UK) Ltd
    Full Title: A Two-Arm Chemoprevention Trial in Familial Adenomatous Polyposis Coli Patients Using the Purified Free Fatty Acid, Eicosapentaenoic Acid.
    Medical condition: Familial adenomatous polyposis (FAP)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059327 Familial adenomatous polyposis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001332-69 Sponsor Protocol Number: PG/04/100/17637 Start Date*: 2005-07-14
    Sponsor Name:University of Aberdeen
    Full Title: A randomised control trial of omega-3 fatty acid on platelet and endothelial function in patients with peripheral arterial disease
    Medical condition: Intermittent claudication
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-004404-21 Sponsor Protocol Number: SLE-Omega Start Date*: 2004-12-10
    Sponsor Name:GreenPark Healthcare Trust [...]
    1. GreenPark Healthcare Trust
    2. Queens University Belfast
    Full Title: Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences
    Medical condition: Systemic Lupus Erythematosus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002386-37 Sponsor Protocol Number: IVN3ICD Start Date*: 2007-08-24
    Sponsor Name:Department of Cardiology, Aalborg Hospital
    Full Title: Intravenous infusion of n-3 polyunsaturated fatty acids and ventricular tackycardi in patients with implantable cardioverter defibrillator (ICD)
    Medical condition: Patients with an implantable cardioverter defibrillator (ICD-unit) for treatment for cardiac ventricular arrhythmias and for prevention of sudden cardiac death
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020943-10 Sponsor Protocol Number: GA10/9312 Start Date*: 2011-03-16
    Sponsor Name:University of Leeds
    Full Title: A randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp) prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme...
    Medical condition: colorectal adenoma (polyp)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10048841 Bowel cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003511-11 Sponsor Protocol Number: D5881C00006 Start Date*: 2015-01-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Two-part, Open-label, Randomised, Crossover, Multicentre, Phase II Study to Investigate the Presence of Pancreatic Exocrine Insufficiency (PEI) in Patients with Type 2 Diabetes Mellitus, and to I...
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) SE (Completed) DK (Completed) HU (Completed) LV (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-005287-94 Sponsor Protocol Number: Stulnig_PUFA1 Start Date*: 2008-05-06
    Sponsor Name:Medizinische Universität Wien
    Full Title: Impact of n-3 Polyunsaturated Fatty Acids on Adipose Tissue Inflammation in Morbidly Obese Patients
    Medical condition: morbid obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027966 Morbid obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011819-20 Sponsor Protocol Number: V00067 CA 201 1A Start Date*: 2009-05-29
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Effects of OMACOR in patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome. A proof of concept study.
    Medical condition: Adult patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome, with implantable cardioverter defibrillator (ICD).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057926 Long QT syndrome congenital LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-003633-33 Sponsor Protocol Number: MAXEPA01 Start Date*: 2011-09-29
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: The effect of purified fish oils on glucose regulation in Congenital Hyperinsulinism of Infancy (CHI)
    Medical condition: Congenital hyperinsulinism
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10062329 Congenital endocrine anomaly PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-015903-22 Sponsor Protocol Number: GA09/9049 Start Date*: 2009-12-15
    Sponsor Name:University of Leeds
    Full Title: THE EFFECT OF EICOSAPENTAENOIC ACID (EPA) ON BIOMARKERS OF GROWTH AND VASCULARITY IN HUMAN COLORECTAL CANCER LIVER METASTASES
    Medical condition: Colorectal cancer liver metastases
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027483 Metastatic neoplasm of liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001396-33 Sponsor Protocol Number: EPA-COV-001 Start Date*: 2020-11-13
    Sponsor Name:SLA Pharma (UK) Ltd [...]
    1. SLA Pharma (UK) Ltd
    2. KD Swiss GmbH
    Full Title: A randomised, double-blind, placebo-controlled study of eicosapentaenoic acid (EPA-FFA) gastro-resistant capsules to treat hospitalised subjects with confirmed SARS-CoV-2
    Medical condition: SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-003544-27 Sponsor Protocol Number: PRV-06009 Start Date*: 2006-07-21
    Sponsor Name:Provident Clinical Research & Consulting, Inc.
    Full Title: An Evaluation of Simvastatin 20 mg Plus Omacor 4 g Compared to Simvastatin 20 mg Plus Placebo in Subjects with Mixed Dyslipidemia
    Medical condition: mixed dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001921-86 Sponsor Protocol Number: S185.4.001 Start Date*: 2007-07-19
    Sponsor Name:Solvay Pharmaceuticals GmbH
    Full Title: A double-blind, placebo-controlled, parallel-group, multi-center study to investigate the effect of Omacor (n-3 PUFA) on lipid parameters in HIV infected patients treated with HAART
    Medical condition: HAART-induced hypertriglyeridemia in HIV infected subjects
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020869 Hypertriglyceridaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001249-41 Sponsor Protocol Number: KEK-ZH-2012-0249 Start Date*: 2013-04-12
    Sponsor Name:University Hospital of Zurich and City Hospital Waid
    Full Title: Vitamin D3 – Omega3 – Home Exercise – HeALTHy Ageing and Longevity Trial Randomized, double-blind, placebo-controlled, multi-centre clinical trial
    Medical condition: healthy ageing, functional decline
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) PT (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002809-34 Sponsor Protocol Number: EPA-POL-04 Start Date*: 2018-08-16
    Sponsor Name:SLA Pharma (UK) Ltd
    Full Title: Randomised, double-blind, placebo-controlled study of the, efficacy, safety and tolerability of EPA-FFA gastro-resistant capsules, in patients with familial adenomatous polyposis (FAP)
    Medical condition: Familial Adenomatous Polyposis (FAP)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10059327 Familial adenomatous polyposis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Ongoing) NL (Completed) DE (Ongoing) DK (Ongoing) PL (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003950-24 Sponsor Protocol Number: EOX1.4 Start Date*: 2012-02-14
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: PHASE II TRIAL OF PALLIATIVE EPIRUBICIN, OXALIPLATIN & CAPECITABINE (EOX) CHEMOTHERAPY COMBINED WITH OMEGA-3 FISH OIL INFUSION (OMEGAVEN) IN PATIENTS WITH OESOPHAGO-GASTRIC CARCINOMA
    Medical condition: Unresectable oesophageal and/or gastric cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006679-18 Sponsor Protocol Number: 10 Start Date*: 2007-03-20
    Sponsor Name:University of Oslo, institute for basic medical sciences, department of nutrition.
    Full Title: Prostate Phytochemical & PUFA Intervention (PFPI) Norwegian title: Prostata Fytokjemikalie & PUFA Intervensjon (PFPI)
    Medical condition: Localized cancer of the prostate.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 08:19:27 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA